Home » Epiphany Begins Valomaciclovir Study
Epiphany Begins Valomaciclovir Study
Epiphany Biosciences has started a Phase II trial with valomaciclovir for acute infectious mononucleosis.
Brian Murphy, Epiphany’s chief medical officer, said the double-blind, placebo-controlled trial will examine fluctuations in viral load as influenced by valomaciclovir and assess symptom scores.
The study will mark the first of several studies of valomaciclovir against Epstein-Barr virus-related diseases.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May